Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RegeneRx Biopharma gets Australian patent
The company said that the new patent will expire in 2023. RegeneRx claims that it holds patents and patent applications worldwide related to its products and holds an
The company said that the new patent will expire in 2023. RegeneRx claims that it holds patents and patent applications worldwide related to its products and holds an
Reportedly, the EMA’s review of the MAA will follow the centralised marketing authorisation procedure and, if the MAA is approved, Pixuvri expects to receive marketing authorisation in the
SCI president Frederick Sancilio said that the expansion of SCI continues with the addition of these two new facilities and the commissioning of the new laboratory in early
Since joining Lundbeck in 1994, Schuberg has held a variety of commercial positions and played an integral role in expanding Lundbeck’s global business. H Lundbeck CEO Ulf Wiinberg
Lubrizol is a US based specialty chemical company that produces ingredients and additives for pharmaceuticals and specialty materials. Lubrizol Advanced Materials focuses on branded specialty polymers and additives
Amatuximab (MORAb-009) is a monoclonal antibody that binds mesothelin, a cell surface protein on pancreatic, mesothelioma and a subset of other types of tumor cells. Morphotek said that
Radie, most recently, served as president and CEO of TransMolecular, a biotechnology company developing new cancer diagnostic and treatment products. Previously, Radie was chief business officer at Prestwick
The panel was convened as a part of the National Coverage Analysis (NCA) that was initiated by the Centers for Medicare and Medicaid Services (CMS). Dendreon claimed that
Provid claimed that this new, highly selective small molecule, PV-267, is designed to block a critical step in the autoimmune process of MS, which leads to the destruction
The Phase II study is expected to investigate the efficacy, safety and tolerability of Cogane administered for 28 weeks to approximately 400 patients with early stage Parkinson’s disease.